Romosozumab, a humanized mouse anti-sclerostin monoclonal antibody was approved for medical use in the United States in 2019 and has since played a critical role in the treatment of both osteoporosis as well as cancer-mediate osteolysis given its unique capabilities as both anti-resorptive and anabolic in bone [79,80,81,82]. This evidence concerns the gene SOST and osteoporosis.